AP-1 transcription factor decoy reduces the TGF-β1-induced cell growth in scleroderma fibroblasts through inhibition of cyclin E
- Author(s)
- JAE-WE CHO; YOUNG-CHANG CHA; KYU-SUK LEE
- Keimyung Author(s)
- Cho, Jae We; Lee, Kyu Suk
- Department
- Dept. of Dermatology (피부과학)
- Journal Title
- Oncology Reports
- Issued Date
- 2008
- Volume
- 19
- Issue
- 3
- Keyword
- scleroderma; transforming growth factor-ß; activator protein-1 oligodeoxynucleotides decoy; cyclin E
- Abstract
- The transforming growth factor-ß (TGF-ß) signaling
pathway plays a key role in the abnormal accumulation of
type I and III collagen of scleroderma. Activator protein-1
(AP-1) is a key regulatory protein in TGF-ß1-induced type I
collagen synthesis. However, it is largely unknown whether
AP-1 is involved in the cell proliferation of fibroblasts in
scleroderma. In this study, we investigated the effects of the
AP-1 oligo-deoxynucleotide (ODN) decoy on TGF-ß1-
induced cell growth in scleroderma fibroblasts. To investigate
the inhibition of AP-1 ODN decoy on the growth rates of
scleroderma fibroblasts through the regulation of cell cycle
regulatory proteins, we transfected the AP-1 ODN decoy on
scleroderma fibroblasts and analyzed the cell cycle
regulatory proteins by RT-PCR and Western blot analysis. We
found that the growth rates of normal fibroblasts and
scleroderma fibroblasts showed similar rates. It is noteworthy
that the scleroderma fibroblasts grew more rapidly than normal
fibroblasts in the presence of TGF-ß1. Moreover, the
transfection of AP-1 decoy ODN into scleroderma fibroblasts
resulted in the down-regulation of the growth rates by the
down-regulation of cyclin E. These results collectively
suggest that AP-1 ODN decoy can down-regulate the growth
rates of scleroderma fibroblasts, thus implying that AP-1 ODN
decoy is a promising therapeutic tool for overcoming
scleroderma.
Key words: scleroderma, transforming growth factor-ß, activator
protein-1 oligodeoxynucleotides decoy, cyclin E
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.